13:12 Thu 25 Jul 2019
Advanced Oncotherapy - Result of AGM
("
Result of AGM
Resolution |
Total votes For1 |
% of votes cast2 |
Total Votes Against |
% of votes cast2 |
Votes Withheld3 |
1. To receive the audited financial statements and the Auditor's and Directors' reports for the year ended |
84,274,491 |
99.99 |
7,976 |
0.01 |
1,130 |
2. To re-appoint |
84,273,267 |
99.99 |
10,330 |
0.01 |
0 |
3. To appoint |
84,272,751 |
99.99 |
10,846 |
0.01 |
0 |
4. To re-appoint |
84,273,267 |
99.99 |
10,330 |
0.01 |
0 |
5. To appoint Dr. |
84,272,751 |
99.99 |
10,846 |
0.01 |
0 |
6. To re-appoint Prof |
84,273,010 |
99.99 |
10,330 |
0.01 |
257 |
7. To re-appoint Dr |
84,273,010 |
99.99 |
10,330 |
0.01 |
257 |
8. To re-appoint |
84,273,010 |
99.99 |
10,330 |
0.01 |
257 |
9. To re-appoint Dr |
84,272,844 |
99.99 |
10,496 |
0.01 |
257 |
10. To appoint |
84,273,010 |
99.99 |
10,330 |
0.01 |
257 |
11. To appoint Prof. |
84,273,010 |
99.99 |
10,330 |
0.01 |
257 |
12. To re-appoint Dr |
84,273,010 |
99.99 |
10,330 |
0.01 |
257 |
13. To appoint |
84,272,751 |
99.99 |
10,846 |
0.01 |
0 |
14. To re-appoint |
84,274,104 |
99.99 |
7,976 |
0.01 |
1,517 |
15. To authorise the Directors to determine the remuneration of the Auditors. |
84,272,837 |
99.99 |
9,930 |
0.01 |
830 |
16. Authority to allot shares
|
84,267,634 |
99.98 |
15,797 |
0.02 |
166 |
17. Authority to disapply pre-emption rights
|
84,212,134 |
99.92 |
71,297 |
0.08 |
166 |
At the AGM the Company gave a presentation to shareholders. This will shortly be available on the website:
https://www.avoplc.com/Investor-Relations/Company-Documents
Notes:
1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution
|
||
Dr. |
Tel: +44 (0)20 3617 8728 |
|
|
|
|
|
|
|
|
|
|
|
Tel: +44 (0)20 3328 5656 |
|
|
|
|
Stifel Nicolaus Europe (Joint Broker) |
|
|
|
Tel: +44 20 7710 7600 |
|
|
|
|
Walbrook PR (Financial PR & IR) |
Tel: +44 (0)20 7933 8780 or avo@walbrookpr.com |
|
|
Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001 |
|
About
Due to the high cost of building and operating traditional proton therapy technologies has meant that the global capacity to treat cancer patients in this way has been extremely low. Only 1% of patients eligible for radiotherapy are being treated with proton therapy currently, with a capacity for as little as 60,000 patients to be treated annually across the globe. Considering the
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE